Bibliography
- Dotis J, Iosifidis E, Ioannidou M, Use of linezolid in pediatrics: a critical review. Int J Infect Dis 2010;14:e638-48
- Taj Y, Abdullah FE, Kazmi SU. Current pattern of antibiotic resistance in Staphylococcus aureus clinical isolates and the emergence of vancomycin resistance. J Coll Physicians Surg Pak 2010;20:728-32
- Hopps E, Caimi G. Exercise in obesity management. J Sports Med Phys Fitness 51:275-82
- Falagas ME, Athanasoulia AP, Peppas G, Effect of body mass index on the outcome of infections: a systematic review. Obes Rev 2009;10:280-9
- Dehghanyar P, Burger C, Zeitlinger M, Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005;49:2367-71
- Sun C, Bai N, Cai Y, Determination the concentration of linezolid in human plasma by HPLC-MS/MS. Zhongguo Lin Chuang Yao Li Xue Za Zhi 2010;26:772-6
- CLSI. Approved Standard. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Clinical and Laboratory Standards Institute;CLSI M07-A8; Wayne, PA: 2009
- CLSI. Approved Guideline. Methodology for the serum bactericidal test. Clinical and Laboratory Standards Institute;CLSI M21-A; Wayne, PA; 1999
- Andes D, van Ogtrop ML, Peng J, In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002;46:3484-9
- Liang B, Wang R. Study on in vitro antimicrobial activity of linezolid,vancomycin and other antibacterials against 111 methicillin resistant staphylococcus aureus. Chin J Clin Pharmacol Ther 2008;13:1044-7
- Eguchi K, Kanazawa K, Shimizudani T, Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation. J Infect Chemother 2010;16:1-9
- Eliopoulos GM. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 2003;36:473-81
- Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010;375:248-51
- Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25:112-18
- Stalker DJ, Jungbluth GL, Hopkins NK, Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239-46
- French G. Linezolid. Int J Clin Pract 2001;55:59-63
- Stein GE, Schooley SL, Peloquin CA, Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427-32
- Kuti JL, Kiffer CR, Mendes CM, Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008;14:116-23
- Di Paolo A, Malacarne P, Guidotti E, Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet 2011;49:439-47
- Jones RN, Ross JE, Bell JM, Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008. Diagn Microbiol Infect Dis 2009;65:404-13
- Niwa T, Suzuki A, Sakakibara S, Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther 2009;31:2126-33
- Matsumoto K, Takeshita A, Ikawa K, Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010;36:179-81